by Jon Fleetwood, Jon Fleetwood:
FDA approved the injection for seniors before any clinical benefit was shown, and before confirming vaccinated can’t shed vaccine components onto unvaccinated, raising informed consent concerns.
Yesterday, Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has “approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.”
Even though the alleged benefit for adults 65 and older was never proven.
The move comes after the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously in June that the “benefits” of Moderna’s experimental mRNA influenza vaccine “outweigh its risks.”
Collectivism is the belief that the group is more important than the individual and that individuals must be sacrificed, if necessary, for the greater good of the greater number.
One of Anthony Fauci’s lawyers became “unruly” after Chairman Rand Paul (R-KY) promised repercussions for Fauci’s refusal to answer lawmakers’ questions during his appearance before the committee, resulting in the lawyer’s removal.
The Pfizer COVID-19 vaccine clinical trial did not establish that the vaccine’s clinically consequential benefits outweighed its potential harms. Nor did the trial establish that vaccination reduced the overall burden of COVID-19-like symptoms, let alone that it reduced person-to-person transmission. More than five years later, revisiting the evidence is essential if we are to avoid repeating the same mistakes when the next public-health emergency arrives.